Novartis Ag

NVS chart

Novartis Ag news

• Sigma Foods reports 3Q26 EBITDA of US $303 million, driven by record Volume, Revenues, and Comparable EBITDA

  Yahoo Finance · Oct 27, 5:00 PM EDT

• Novartis' 'Critically' Important Update Ahead Of November

  Yahoo Finance · Oct 27, 4:27 PM EDT

• Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority Brand ...

  Yahoo Finance · Oct 27, 3:03 PM EDT

• Novartis (NVS) Q3 2026 Earnings Call Transcript

  fool.com · Oct 27, 12:46 PM EDT

• 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential

  Yahoo Finance · Oct 27, 11:16 AM EDT

• NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

  Yahoo Finance · Oct 27, 10:49 AM EDT

• [Novartis AG Q3 2026 Earnings Call] Novartis Raises 2026 Core Profit Guidance After 10% Core Operating Income Growth, But $1.9 Billion Impairment From Failed Muscle Disease Trial Drags Reported Net Income Down 71%

  BigGo Finance · Oct 27, 10:34 AM EDT

• Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment

  proactiveinvestors.com · Oct 27, 9:05 AM EDT

• Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

  Yahoo Finance · Oct 27, 8:30 AM EDT

• NOVARTIS AG N (NOTA.DU) Q3 FY2026 earnings call transcript

  Yahoo Finance · Oct 27, 8:00 AM EDT

• The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP

  Yahoo Finance · Oct 27, 7:46 AM EDT

• Novartis Raises 2026 Profit Forecast After Q3 Sales Rise 4% to $14.52 Billion

  investorshub.advfn.com · Oct 27, 7:31 AM EDT

Novartis Ag key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-K6-K2026-10-27
• 6-KFORM 6-K2026-09-08
• 6-KFORM 6-K2026-09-04
• 6-KFORM 6-K2026-09-01
• 6-K6-K2026-07-21
• 6-KFORM 6-K2026-06-11
• 6-K6-K2026-04-28
• 6-KFORM 6-K2026-03-18
• 6-K6-K2026-02-04
• 6-K6-K2026-02-04
• 20-F20-F2026-02-04
• 6-KFORM 6-K2025-11-25

About Novartis Ag

Ticker

NVS (NYSE)

Industry

Pharmaceutical Preparations

Headquarters

Basel, Switzerland

Incorporated in

Switzerland

Fiscal year end

December 31

SEC CIK

1114448

Frequently asked questions